Multicenter Prospective Investigation on Efficacy and Safety of Carperitide as a First-Line Drug for Acute Heart Failure Syndrome With Preserved Blood Pressure  COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study

Nomura, F; Kurobe, Nobushige; Mori, Yuichi; Hikita, Atsushi; Kawai, Masashi; Suwa, Mitsuru; Okutani, Yukihiro

doi:10.1253/circj.cj-07-0760

Cited by 84 publications

(54 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human ANP (carperitide) is frequently used for the treatment of acute HF in Japan. [39][40][41] It was recently reported that infusion of human ANP reduced the infarct size and improved cardiac function in patients with acute myocardial infarction. 42,43 BNP is used for the diagnosis of HF and for evaluating the severity of failure.…”

Section: Microarray Analysismentioning

confidence: 99%

Global Gene Expression Profiling in the Failing Myocardium

Asakura

Kitakaze

2009

Circ J

View full text Add to dashboard Cite

Heart failure (HF) is a syndrome that involves multiple cellular mechanisms leading to a common phenotype of reduced ventricular contraction and cardiac chamber dilation. To clarify the mechanisms, a number of microarray analyses of the failing myocardium have been conducted. Gene expression profiles are usually compared between opposing pairs of samples, such as non-failing vs failing hearts, ischemic vs non-ischemic hearts, male vs female failing hearts or atria vs ventricles of failing hearts. Apart from these conventional methods, a different novel approach identified cardiac myosin light chain kinase (MLCK) as a HF-related gene by the comprehensive search for the genes that had an expression level that strongly correlated with the severity of HF; further investigations proved the important role of cardiac MLCK in HF. Moreover, a robust gene expression signature composed of 27 genes was revealed on analysis of 4 independent microarray data sets from the failing myocardium of dilated cardiomyopathy. The authors newly demonstrate 107 HF-related genes that were listed in 2 or more of 7 microarray data sets previously reported. Among these genes, many were observed to be involved in mitochondrial dysfunction and oxidative phosphorylation and 3 extracellular molecules, including periostin, pleiotrophin, and SERPINA3, which might become novel diagnostic and therapeutic targets for HF. These novel strategies warrant the new identification of specific genes that are linked to the pathophysiology of HF. (Circ J 2009; 73: 1568 -1576

show abstract

Section: Microarray Analysismentioning

confidence: 99%

Global Gene Expression Profiling in the Failing Myocardium

Asakura

Kitakaze

2009

Circ J

View full text Add to dashboard Cite

show abstract

“…6) Several reports revealed the efficacy and safety of carperitide in acute phase treatment and improvement of long-term prognosis after administration of carperitide in patients with heart failure. 7,8) Tolvaptan, which is an orallyadministered selective vasopressin V 2 receptor antagonist that promotes aquaresis, 9) improves signs and symptoms in ADHF patients without serious adverse events. 10) We previously demonstrated that tolvaptan showed less blood pressure reduction and higher daily urine volume than carperitide in ADHF patients in an acute heart failure volume control multicenter randomized (AVCMA) trial.…”

mentioning

confidence: 99%

Vasopressin V<sub>2</sub> Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood Pressure

Suzuki¹,

Yoshihisa²,

Yamaki³

et al. 2015

Int. Heart J.

View full text Add to dashboard Cite

on behalf of the AVCMA investigators SummaryDiuresis is a major therapy for the reduction of congestive symptoms in acute decompensated heart failure (ADHF) patients. Carperitide has natriuretic and vasodilatory effects, and tolvaptan produces water excretion without electrolyte excretion. We previously reported the usefulness of tolvaptan compared to carperitide in ADHF patients with fluid volume retention. The purpose of this study was to examine whether the efficacy of tolvaptan was altered in ADHF patients with reduced left ventricular systolic function and in those with hypotension. A total of 109 hospitalized ADHF patients were randomly assigned to either a tolvaptan or a carperitide treatment group. Baseline clinical characteristics were not different between the two groups. We divided these patients based on the left ventricular ejection fraction (EF) by echocardiography, and blood pressure (BP) at the time of admission. Daily urine volume between the tolvaptan and carperitide groups in patients with preserved EF (≥ 50%) was not different, however, in those with reduced EF (< 50%), the urine volume was significantly higher in the tolvaptan group than in the carperitide group (day 2, 3, 4, P < 0.05 for all). Daily urine volume did not differ between these two groups in the high blood pressure group (BP ≥ 140 mmHg), but was significantly higher in the tolvaptan group than in the carperitide group (day 1, P = 0.021; day 3, P = 0.017) in the low blood pressure group (BP < 140 mmHg). The present study reveals that tolvaptan is more effective than carperitide, especially in ADHF patients with reduced left ventricular systolic function and without hypertension. (Int Heart J 2015; 56: 213-218)

show abstract

“…2,[5][6][7][8][9][10][11][12] It is also used as a drug for acute heart failure, as it has an effect to improve acute-phase hemodynamics. Furthermore, based on clinical findings suggesting that the agent might have a cardioprotective effect in patients with acute myocardial infarction, a cardioprotective action that goes beyond hemodynamic improvement in the acute phase is also expected.…”

Section: Discussionmentioning

confidence: 99%

“…A hANP preparation, carperitide, was subsequently developed, and has been used mainly for the treatment of heart failure and acute myocardial infarction (AMI), because it improves preload and afterload by diuresis and vasodilatation. [2][3][4][5][6][7] ANP has been demonstrated to exert various effects, including inhibition of the renin-angiotensin-aldosterone system, reduced myocardial hypertrophy, improved cardiac function, and less remodeling, and fibrosis. [8][9][10][11][12] During cardiac operations performed in our department, we have administered an intravenous infusion of lowdose ANP at the onset of cardiopulmonary bypass (CPB)…”

Section: Introductionmentioning

confidence: 99%

Effects of Continuous Infusion of Low-dose Human Atrial Natriuretic Peptide (hANP) on the Lungs during Cardiac Surgery

Shibasaki

Fukuda

Yamada

et al. 2015

ATCS

View full text Add to dashboard Cite

Objective: The objective of this study was to determine the effects of a continuous infusion of low-dose hANP on the lungs during cardiac surgery in patients under cardiopulmonary bypass (CPB). Methods: We analyzed 30 consecutive cases of cardiac surgery performed at our hospital from 2007-2008. The patients were divided into a group that received hANP (hANP group) or a group that received saline and no hANP (N-hANP group). We measured various parameters before and after surgery using a PiCCO monitor. Result: There were no differences in the preoperative characteristics between the groups, although urine volume during the operation was significantly greater in the hANP group. After surgery, there were no significant differences between the groups in cardiac output index (CI), global enddiastolic volume index (GEDVI), intrathoracic blood volume index (ITBI), pulmonary blood volume index (PBI), extravascular lung water index (ELWI) and pulmonary vascular permeability index (PVPI), total protein, and creatine. In contrast, interleukin-6 (IL-6) and renin were significantly lower, and albumin was significantly higher in the hANP group. Conclusion: We found that low-dose hANP during open cardiac surgery inhibited the secretion and plasma activity of IL-6 and renin. Although there were no differences in lung circulatory parameters such as the amount of fluid in the pulmonary blood vessels between the two groups, we believe that the strong diuretic effect of hANP reduced third-space fluid retention caused by CPB.

show abstract

Multicenter Prospective Investigation on Efficacy and Safety of Carperitide as a First-Line Drug for Acute Heart Failure Syndrome With Preserved Blood Pressure COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study

Cited by 84 publications

References 20 publications

Global Gene Expression Profiling in the Failing Myocardium

Global Gene Expression Profiling in the Failing Myocardium

Vasopressin V<sub>2</sub> Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood Pressure

Effects of Continuous Infusion of Low-dose Human Atrial Natriuretic Peptide (hANP) on the Lungs during Cardiac Surgery

Contact Info

Product

Resources

About